PUBLICATIONS
ORIGINAL REPORTS
1. Richter JM, Kushkuley S, Barrett JA, Oster G. Treatment of new-onset ulcerative colitis and ulcerative proctitis: a retrospective study. Aliment Pharmacol Ther 2012; 36: 248–256.
2. Arnold LM, Leon T, Whalen E, Barrett J. Relationships among pain and depressive and anxiety symptoms in clinical trials of pregabalin in fibromyalgia. Psychosomatics. 2010 Nov; 51(6):489-97.
3. Boulac M, Leon T, O’Brien T; Whalen E; Barrett JA; Giordano S. A comparison of pregabalin, lamotrigine, and placebo as adjunctive therapy in patients with refractory. partial-onset seizures. Epilepsy Research September 2010; 91 (1): 10-19.
4. Tuchman M, Barrett JA, Donevan S, Hedberg TG, Taylor CP. Central Sensitization and Ca(V)alpha(2)delta Ligands in Chronic Pain Syndromes: Pathologic Processes and Pharmacologic Effect. J Pain. 2010 Dec;11(12):1241-9
5. Russell IJ, Crofford LJ, Leon T, Cappelleri JC, Bushmakin AG, Whalen E, Barrett JA, Sadosky AB. The Effects of Pregabalin on Sleep Disturbance Symptoms Among Individuals with Fibromyalgia Syndrome. Sleep Medicine Jun; 10 (6):604-10, 2009.
6. Ramsay RE, Perucca E, Robbins J, Barrett JA, Spiegel K. Rapid onset of seizure suppression with pregabalin adjunctive treatment in patients with partial seizures. Epilepsia Aug; 50 (8):1891-8, 2009.
7. Stacey BR, Barrett JA, Whalen E, Phillips KF, Rowbotham MC. Pregabalin for postherpetic neuralgia: placebo-controlled trial of fixed and flexible dosing regimens on allodynia and time to onset of pain relief. J of Pain, 9(11)1006-1017, 2008.
8. Arnold LM, Russell IJ, Diri EW, Duan WR, Young, Jr. JP, Sharma U, Martin SA, Barrett JA, Haig G. A 14-week, randomized, double-blind, placebo-controlled monotherapy trial of pregabalin in patients with fibromyalgia. J of Pain. 9(9) 792-805, 2008.
9. Frame B, Beal SL, Miller R, Barrett JA, Burger P. Mixed Effects Modeling of Weight Change Associated with Placebo and Pregabalin Administration. J Pharmacokinet Pharmacodyn. 2007 Dec;34(6):753-70
10. Hitiris N, Barrett JA, Brodie MJ. Erectile dysfunction associated with pregabalin add-on treatment in patients with partial seizures: Five case reports. Epilepsy & Behavior, 8(2) 418-421, 2006.
11. Elger CE, Brodie MJ, Anhut H, Lee, CM, Barrett JA. Pregabalin Add-on treatment in Patients with Partial Seizures: A Novel Evaluation of Flexible-dose and Fixed-dose Treatment in a Double-blind, Placebo-controlled Study. Epilepsia, 46(12), 1926-1936, 2005.
12. Osterloh, IH, Barrett JA, Glasser DB, Tonic-clonic seizures in patients taking sildenafil. http://bmj.com/cgi/eletters/325/7369/869#27135, 18 Nov 2002.
13. Barrett JA, Edinger H, Siegel A, Intrahypothalamic injections of norepinephrine facilitate feline affective aggression via alpha-2 adrenoceptors. Brain Research, 525, 285-293, 1990.
14. Barrett JA, Shaikh MB, Edinger H, Siegel A, The effects of intrahypothalamic injections of norepinephrine upon affective defense behavior in the cat. Brain Research, 426(2), 381-384, 1987.
15. Shaikh MB, Barrett JA, Siegel A, The pathways mediating mediating affective defense and quiet biting attack behavior from the midbrain central gray of the cat. Brain Research, 437(1), 9-25, 1987.
ABSTRACTS
1. Richter JM, Kushkuley S, Barrett JA, Oster G. Treatment of Newly Diagnosed Ulcerative Colitis in Community-Based Practice. Digestive Disease Week, Annual Meeting, Chicago, IL, May 2011.
2. Sanderson S.J., Barrett JA, Swanson H. “Ulcerative proctitis Patient’s preference for topical formulations of mesalamine” Advances in IBD Hollywood, FL Accepted as a poster on Oct 13 2010. Inflammatory Bowel Diseases. 2011. Vol. 17, Issue S1, Pages S1-75
3. Sanderson S, Swanson H, Barrett J. Ulcerative Proctitis Patients’ Preference for Topical Formulations of Mesalamine. American College of. Gastroenterology, Annual Meeting, San Antonio, TX, Oct 2010.
4. Barrett J, Russell, IJ, Pauer L., Whalen, E. Pregabalin (Lyrica) Treatment Effects: Correlations of Sleep Diaries with Medical Outcomes Sleep Scale (MOS-SS) in Fibromyalgia (FM) Patients in Two Studies. American Academy of Neurology, Chicago, IL. USA, April 12-19, 2008.
5. Arnold, L., Pauer, L., Whalen, E., Barrett J. Pregabalin (Lyrica) Pain Changes Associate with Anxiety and Depression Changes in Fibromyalgia Patients. American Academy of Neurology, Chicago, IL. USA, April 12-19, 2008.
6. Arnold, L., Pauer, L., Whalen, E., Barrett J. Pregabalin (Lyrica) Improves Pain in Fibromyalgia (FM) Patients Regardless of Baseline Anxiety and Depression Levels. American Academy of Neurology, Chicago, IL. USA, April 12-19, 2008.
7. Tuchman M, Barrett JA, Edith Durso-Decruz E, Murphy TK. Pregabalin and central sensitization in chronic pain syndromes: evidence supporting a common pharmacologic effect. American Academy of Neurology, Chicago, IL. USA, April 12-19, 2008.
8. Barrett JA, Freynhagen R, Stacey B, Whalen E, Phillips K, Murphy TK. Effect of Pregabalin on Dynamic Allodynia in Patients With Postherpetic Neuralgia (PHN): Results From a Double-Blind, Randomized, Controlled Trial. American Academy of Neurology, Chicago, IL. USA, April 12-19, 2008.
9. T. Leon, Zeiher, B., Pauer, L., Whalen, E., Barrett J. Pregabalin Monotherapy for Relief of Pain Associated with Fibromyalgia: Durability of Pain Results of a 14-Week, Double-Blind, Placebo-Controlled Trial. European Congress of Psychiatry (AEP), Nice, France, April5-9, 2008.
10. Arnold L, Pauer L, Whalen E, Barrett J, Leon T. Fibromyalgia patients treated with pregabalin (lyrica) experience improved pain reduction regardless of baseline anxiety and depression levels. J of Pain, 9(4) Supplement 1, p48, April 2008.
11. Tuchman M, Durso-DeCruz E, Murphy T, Barrett J. Central sensitization, chronic pain syndromes, and pregabalin. . J of Pain, 9(4) Supplement 1, p49, April 2008.
12. Russell I, Pauer L, Whalen E, Barrett J. Treatment effects on changes in pain and changes in sleep: Pregabalin (lyrica) in fibromyalgia patients. J of Pain, 9(4) Supplement 1, p49, April 2008.
13. Russell I, Pauer L, Whalen E, Barrett J. Pregabalin (lyrica) treatment effects: Correlations of sleep diaries with Medical Outcomes Sleep Scale (MOS-SS) in fibromyalgia patients in two studies. J of Pain, 9(4) Supplement 1, p47, April 2008.
14. Barrett J, Freynhagen R, Whalen E, Phillips K, Durso-DeCruz E. Effect of pregabalin on dynamic allodynia in patients with postherpetic neuralgia (PHN): Results from a double-blind, randomized, controlled trial (RCT). J of Pain, 9(4), Supplement 1, p47 April 2008.
15. Leon, T., Whalen, E., Arnold, L., Pauer, L., Barrett, J. Pregabalin Improves pain in fibromyalgia (FM) patients regardless of baseline anxiety and depression levels. American Academy of Neurology, Chicago, IL. USA, April 12-19, 2008.
16. Barrett, J., Zeiher, B., Pauer, L., Whalen, E., Leon, T. Pregabalin (Lyrica) As Long-Term Treatment of Fibromyalgia Pain. American Academy of Neurology, Chicago, IL. USA, April 12-19, 2008.
17. Barrett JA, Leon T, Pauer L, Whalen E. Pregabalin as Long-Term Treatment of Fibromyalgia Pain. Arch Phys Med Rehabil 89(11):e116-e117. 2008.
18. Barrett JA and Pauer L. Fibromyalgia Relapse Evaluation and Efficacy for Durability of Meaningful Relief (FREEDOM) Trial: A 6 Month discontinuation Trial of Pregabalin for the Pain of Fibromyalgia. Arch. Phys. Med. Rehabil. 89(11)e116-e116.
19. Leon T., Pauer, L. Whalen, E., Barrett, J. Efficacy of Pregabalin (Lyrica) Monotherapy for Improving Sleep Outcomes in Patients with Fibromyalgia: Results of a 14-Week, Double-Blind, Placebo-Controlled Trial. American Academy of Neurology, Chicago, IL. USA, April 12-19, 2008.
20. Simpson SL,Young, Jr JP,Haig G, Barrett JA. Pregabalin Therapy for Durability of Meaningful Relief of Fibromyalgia. . American College of Rheumatology-71st Annual Scientific Meeting, Boston, MA, November 6-11, 2007.
21. Duan WR, Florian H,Young, Jr JP, Martin S, Haig G, Barrett J, T Leon. Pregabalin Monotherapy for Management of Fibromyalgia: Analysis of Two Double-Blind, Randomized, Placebo-Controlled Trials. American College of Rheumatology-71st Annual Scientific Meeting, Boston, MA, November 6-11, 2007.
22. Rowbotham MC, Stacey BR, Phillips K, Whalen E, Murphy TK, Barrett JA. A Double-Blind, Randomized, Placebo-controlled Trial To Evaluate Time-To-Onset Of Clinically Meaningful Pain Relief In Postherpetic Neuralgia (PHN) Patients Treated With Pregabalin. 2nd International Congress on Neuropathic Pain, Berlin, Germany, June 7-10, 2007.
23. Rosenstock J, Arezzo J, Pauer L, LaMoreaux L, Barrett J, Durso-De Cruz E. Pregabalin as Treatment of Painful Diabetic Peripheral Neuropathy (DPN): Nerve Conduction and Analgesic Effect in A 13-Week-Double-Blind, Placebo-Controlled Trial. American Pain Society 26th Annual Scientific Meeting, Washington D.C. May 2-5, 2007.
24. Crofford LJ, Simpson SL, Young JP, Haig GM, Barrett JA. Fibromyalgia Relapse Evaluation and Efficacy for Durability of Meaningful Relief (FREEDOM) Trial: A 6-Month, Double-Blind, Placebo-Controlled Trial of Treatment With Pregabalin. American Pain Society 26th Annual Scientific Meeting, Washington D.C., May 2-5, 2007.
25. Stacey B, Barrett J, Whalen E, Chambers R, Phillips K. A Double-Blind, Randomized, Placebo-Controlled Trial of Pregabalin: Time to Onset of Meaningful Pain Relief in Patients With Postherpetic Neuralgia (PHN). American Pain Society 26th Annual Scientific Meeting, Washington D.C., May 2-5, 2007.
26. Barrett JA, Murphy TK, Siddall PJ, Griesing T, Does The Presence Of Comorbid Anxiety Symptoms Influence The Efficacy Of Pregabalin For Treating Central Neuropathic Pain In Patients With Spinal Cord Injury? The International Conference on the Mechanisms and Treatment of Neuropathic Pain, Bermuda, Nov 2-4, 2006.
27. Miller R, Bockbrader H, Chapel S, Barrett JA. Pharmacodynamic Comparison of Pregabalin and Gabapentin. European Federation of Neurological Societies, Glasgow, Scotland, Sept 2-5, 2006.
28. Miller R, Beal SL, Frame B, Barrett JA, Burger P. Modeling Of Weight Change Associated With Pregabalin And Placebo Administration. European Federation Of Neurological Societies, Glasgow, Scotland, Sept 2-5, 2006.
29. Uthman BM, Bazil C, Griesing T, Whalen E, Spiegel K, Barrett JA, Long-Term Seizure Freedom in Patients with Partial Seizures Treated with Add-On Pregabalin: Analysis of Open-Label Studies. European Congress Epilepsy, Helsinki, Finland, July 2-7, 2006.
30. Spiegel K, Bazil C, Uthman BM, Barrett JA, Whalen E, Griesing T, Baldinetti F, Long-Term Response in Patients with Partial-Onset Seizures Treated with Add-On Pregabalin. European Congress Epilepsy, Helsinki, Finland, July 2-7, 2006.
31. Miller R, Beal SL, Frame B, Barrett JA, Burger P, Modeling of Weight Change Associated with Placebo and Pregabalin Administration. European Congress Epilepsy, Helsinki, Finland, July 2-7, 2006.
32. Bockbrader H, Miller R, Chapel S, Barrett JA. Pharmacodynamic Comparison of Pregabalin and Gabapentin. European Congress Epilepsy, Helsinki, Finland, July 2-7, 2006.
33. Barrett J, Miller R, Elger CE, Frame B, Hoppe C, Beal SL, Predictive Performance of Weight Change Associated with Pregabalin Administration European Congress Epilepsy, Helsinki, Finland, July 2-7, 2006.
34. Baldinetti F, Uthman BM, Bazil C, Barrett JA, Whalen E, Spiegel K, Griesing T. Safety and Tolerability Profile of Pregabalin in the Long-Term Treatment of Patients with Partial-Onset Seizures. European Congress Epilepsy, Helsinki, Finland, July 2-7, 2006.
35. Bazil C, Uthman BM, Barrett JA, Huang S, Spiegel K,Griesing T. Long-Term Response In Patients With Partial Seizures Treated With Add-On Pregabalin. American Academy of Neurology 58th Annual Meeting, San Diego, CA, April 1-8, 2006.
36. Miller R, Bockbrader H, Chapel S, Barrett JA. Pharmacodynamic Comparison of Pregabalin and Gabapentin. American Academy of Neurology 58th Annual Meeting, San Diego, CA, April 1-8, 2006.
37. Bockbrader H, Miller R, Spiegel K, Barrett JA, and Wesche D, The Pharmacokinetic And Pharmacodynamic Properties Of Pregabalin And Gabapentin In Epilepsy: Differences And Similarities. Epilepsia, 46 (Suppl. 8), 2005.
38. Spiegel K, Anhut H, Griesing T, Huang S, and Barrett J, Pregabalin As Add-On Treatment For Partial Seizures With Or Without Secondary Generalizations: Efficacy, Safety, And Tolerability Findings From The Analysis Of Four Randomized Clinical Trials. Epilepsia, 46 (Suppl. 8), 2005.
39. Bockbrader H, Miller R, Frame B, Lalonde R, Spiegel K, and Barrett J, The Concomitant Use Of Pregabalin And Oral Contraceptives Does Not Affect The Efficacy Of Either Agent. Epilepsia, 46 (Suppl. 8), 2005.
40. Barrett J, Huang S, and Spiegel K, Multi-Trial Analysis of the Duration and Intensity of Adverse Events Associated With Pregabalin Adjunctive Treatment of Partial Seizures. Epilepsia, 46 (Suppl. 8), 2005.
41. Elger CE, Brodie MJ, Anhut H, Lee CM, and Barrett JA. Novel Evaluation of Flexible-dose and Fixed-dose Treatment in a Double-blind, Placebo-controlled Study. Epilepsia; 46 (12), 2005.
42. Spiegel K, Anhut H, Huang S, Barrett J, The Efficacy, Safety, and Tolerability of Pregabalin as Add-On Treatment for Partial Seizures With or Without Secondary Generalizations: Findings from the Analysis of Four Randomized Clinical Trials. 9th Congress of the European Federation of Neurological Societies, Athens, Greece, September 17-20, 2005.
43. Barrett J, Huang S, Spiegel K, Add-on Treatment of Partial Seizures with Pregabalin is not Affected by the Concomitant Use of an Oral Contraceptive or by Menopausal Status. 9th Congress of the European Federation of Neurological Societies, Athens, Greece, September 17-20, 2005.
44. Spiegel K, Anhut H, Huang S, Barrett J, The efficacy, safety, and tolerability of pregabalin as add-on treatment for partial seizures with or without secondary generalizations: findings from the analysis of four randomized clinical trials. International Epilepsy Congress, Paris, France, August 28-September 1, 2005.
45. Barrett J, Huang S, Spiegel K, Add-on treatment of partial seizures with pregabalin is not affected by the concomitant use of an oral contraceptive or by menopausal status. International Epilepsy Congress, Paris, France, August 28-September 1, 2005.
46. Barrett J, Huang S, Spiegel K, Adverse Events Associated with Pregabalin Adjunctive Treatment of Partial Seizures Are Generally Short Lived. Neurology. 2005 Mar; 64 (Suppl 1): A191. [P03.113] American Academy of Neurology 57th Annual Meeting, Miami Beach, FL, April 9 – April 16, 2005.
47. Barrett J, Lee CM, Greiner MJ, et al., Seizure frequency and number of concomitant antiepileptic drugs do not limit the efficacy of pregabalin as add-on treatment of partial seizures. J Neurol. 2004 Jun; 251 Suppl 3:III132. 14th Meeting of the European Neurological Society, Barcelona, Spain, June 26 – June 30, 2004.
48. Spiegel K, Barrett J, Lee CM, et al., Pregabalin efficaciously reduces simple partial, complex partial, and secondarily generalized seizures. Eur J Neurol. 2004 Sept; 11 Suppl 2:77. 8th Congress of the European Federation of Neurological Societies, Paris, France, September 4 – September 7, 2004.
49. Morrell M, Barrett J, et al., Pharmacokinetics of Pregabalin and its Effects on Concomitantly Administered Oral Contraceptives and Antiepileptic Drugs. American Epilepsy Society’s 58th Annual Meeting, New Orleans, LA, December 3-7, 2004.
50. Barrett J, Epilepsy Severity is Not a Determinant of Pregabalin’s Efficacy as Treatment of Partial Seizures. American Epilepsy Society’s 58th Annual Meeting, New Orleans, LA, December 3-7, 2004.
51. Barrett J, Lee C, Spiegel K, et al. The efficacy of pregabalin as add-on treatment of partial seizures does not appear to be limited by duration of epilepsy diagnosis and number of concomitant antiepileptic drugs. Epilepsia, 45(Suppl.7):74. American Epilepsy Society’s 58th Annual Meeting, New Orleans, LA, December 3-7, 2004.
52. Barrett JA, Silverman A-J, Kelly DD, Response of corticotropin-releasing hormone (CRH) neurons to chronic behavioral stress does not require adrenal steroid secretion. Annual Meeting of the Endocrine Society, San Antonio, Texas, June 1992.
53. Barrett JA, Silverman A-J, Kelly DD, Rapid co-production of vasopressin and corticotropin releasing hormone within select paraventricular neurosecretory cells following behavioral stress. Society for Neuroscience Abstracts, 17, 1358, 1991.
54. Sloan RP, Barrett JA, Murphy C, Potegal M, Myers MM, Intracerebroventricular propranolol enhances cardiac vagal tone during stress in rats. Annual Meeting of the American Psychosomatic Society, Sante Fe, New Mexico, 53, 224, 1991.
55. Barrett JA, Silverman A-J, Hou-Yu A, Kelly DD, Chronic behavioral stress increases CRF immunoreactivity and CRF/VP co-localization. Society for Neuroscience Abstracts, 15, 135, 1989.
56. Barrett JA, Edinger H, Siegel A, The effect of intrahypothalamic injections of Ro4-1284 upon feline affective defense. Sixth International Catecholamine Symposium, Jerusalem, Israel, June 14-19, 1987.
57. Barrett JA, Edinger H, Siegel, A, The effect of intrahypothalamic injections of norepinephrine upon aggressive behavior in the cat. 71st Annual Meeting of the Federation of American Societies for Experimental Biology, 46, 547, 1987.
58. Brutus M, Shaikh MB, Edinger H, Ritter A, Barrett JA, Siegel A, Effects of amygdaloid seizures upon hypothalamically elicited affective defense behavior in the cat. Society for Neuroscience Abstracts, 10, 602, 1984.